Laboratory of Physiologic Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD.
Hepatology. 2019 Apr;69(4):1535-1548. doi: 10.1002/hep.30364. Epub 2019 Mar 6.
Endocannabinoids promote energy conservation in obesity, whereas cannabinoid-1 receptor (CB R) blockade reverses body weight gain and insulin resistance and increases energy expenditure. Here we investigated the molecular mechanisms of the catabolic effects of CB R blockade in the liver. Exposure of primary mouse hepatocytes and HepG2 cells to the CB R agonist arachidonyl-2'-chloroethylamide inhibited the expression of Sirtuin-1 (Sirt1) and Rictor, a component of mechanistic target of rapamycin complex 2 (mTORC2) and suppressed insulin-induced Akt phosphorylation at serine 473. These effects were reversed by peripheral CB R antagonist JD5037 in control hepatocytes but not in hepatocytes deficient in Sirt1 and/or Rictor, indicating that these two proteins are required for the CB R-mediated inhibition of insulin signaling. Feeding C57BL/6J mice a high-fat diet (HFD) inhibited hepatic Sirt1/mTORC2/Akt signaling, and the inhibition was reversed by rimonabant or JD5037 in wild-type but not liver-specific Sirt1 (Sirt1-LKO) mice, to levels observed in hepatocyte-specific CB R mice. A similar attenuation of hyperglycemia and hyperinsulinemia in wild-type mice with obesity but not in Sirt1-LKO mice could be attributed to insufficient reversal of HFD-induced mitochondrial reactive oxygen species generation in peripheral tissues in the latter. In contrast, JD5037 treatment was equally effective in HFD-fed wild-type and Sirt1-LKO mice in reducing hepatic steatosis, increasing fatty acid β-oxidation, and activating 5'adenosine monophosphate-activated protein kinase (AMPK) through liver kinase B1 (LKB1), resulting in a similar increase in total energy expenditure in the two strains. Conclusion: Peripheral CB R blockade in mice with obesity improves glycemic control through the hepatic Sirt1/mTORC2/Akt pathway, whereas it increases fatty acid oxidation through LKB1/AMPK signaling.
内源性大麻素促进肥胖中的能量守恒,而大麻素受体 (CB R) 阻断可逆转体重增加和胰岛素抵抗,并增加能量消耗。在这里,我们研究了 CB R 阻断在肝脏中的分解代谢作用的分子机制。暴露于 CB R 激动剂花生四烯酰-2'-氯乙酰胺的原代小鼠肝细胞和 HepG2 细胞抑制 Sirtuin-1 (Sirt1) 和雷帕霉素复合物 2 (mTORC2) 的组成部分 Rictor 的表达,并抑制胰岛素诱导的 Akt 丝氨酸 473 磷酸化。这些作用在对照肝细胞中被外周 CB R 拮抗剂 JD5037 逆转,但在 Sirt1 和/或 Rictor 缺陷的肝细胞中未被逆转,表明这两种蛋白是 CB R 介导的胰岛素信号抑制所必需的。用高脂肪饮食 (HFD) 喂养 C57BL/6J 小鼠抑制了肝脏中的 Sirt1/mTORC2/Akt 信号传导,并且在野生型但不是肝脏特异性 Sirt1 (Sirt1-LKO) 小鼠中,雷莫芦单抗或 JD5037 逆转了这种抑制作用,使其恢复到肝细胞特异性 CB R 小鼠中的水平。肥胖野生型小鼠的高血糖和高胰岛素血症的类似衰减,但在 Sirt1-LKO 小鼠中则不能归因于后者外周组织中 HFD 诱导的线粒体活性氧生成的逆转不足。相比之下,JD5037 处理在 HFD 喂养的野生型和 Sirt1-LKO 小鼠中同样有效,可减少肝脂肪变性,增加脂肪酸β氧化,并通过肝激酶 B1 (LKB1) 激活 5'腺苷单磷酸激活蛋白激酶 (AMPK),从而使两种品系的总能量消耗均增加。结论:肥胖小鼠外周 CB R 阻断通过肝脏 Sirt1/mTORC2/Akt 途径改善血糖控制,而通过 LKB1/AMPK 信号增加脂肪酸氧化。